Canada's Angiochem outlines plans for advancing product candidates and deal with Geron

9 December 2010

Privately-held Canadian group Angiochem has announced its plans for advancing the development of product candidates from its pipeline, using the company’s proprietary platform for Engineered Peptide Compounds (EPiC) for drugs that cross the blood-brain barrier through LRP-1 targeting.

The product candidates cover a range of therapeutic areas, including pain, obesity and Parkinson’s disease, using Angiochem’s technology to uniquely enable drugs to penetrate the CNS, including biologics (peptides and proteins) and small molecules. In addition, Angiochem will continue to actively pursue additional research and development collaborations.

"We are excited to move forward with our diverse product portfolio, based on the validation of our receptor-targeting peptide technology and the strengthened resources provided by the $35 million up-front payment, comprised of $7.5 million in cash and $27.5 million of shares of Geron (Nasdaq: GERN) common stock to be issued in January 2011, related to the recently announced license and collaboration agreements with Geron,” commented Jean-Paul Castaigne, president and chief of Angiochem.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical